These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27737934)

  • 21. Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
    Shi Y; Xu L; Tang J; Fang L; Ma S; Ma X; Nie J; Pi X; Qiu A; Zhuang S; Liu N
    Am J Physiol Renal Physiol; 2017 Mar; 312(3):F502-F515. PubMed ID: 28052874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of deacetylation activity of Hdac6 affects emotional behavior in mice.
    Fukada M; Hanai A; Nakayama A; Suzuki T; Miyata N; Rodriguiz RM; Wetsel WC; Yao TP; Kawaguchi Y
    PLoS One; 2012; 7(2):e30924. PubMed ID: 22328923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration.
    Williams KA; Zhang M; Xiang S; Hu C; Wu JY; Zhang S; Ryan M; Cox AD; Der CJ; Fang B; Koomen J; Haura E; Bepler G; Nicosia SV; Matthias P; Wang C; Bai W; Zhang X
    J Biol Chem; 2013 Nov; 288(46):33156-70. PubMed ID: 24089523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
    Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
    Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
    Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
    Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deacetylation of α-tubulin and cortactin is required for HDAC6 to trigger ciliary disassembly.
    Ran J; Yang Y; Li D; Liu M; Zhou J
    Sci Rep; 2015 Aug; 5():12917. PubMed ID: 26246421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibiting histone deacetylase 6 partly protects cultured rat cortical neurons from oxygen‑glucose deprivation‑induced necroptosis.
    Yuan L; Wang Z; Liu L; Jian X
    Mol Med Rep; 2015 Aug; 12(2):2661-7. PubMed ID: 25976407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
    Haggarty SJ; Koeller KM; Wong JC; Grozinger CM; Schreiber SL
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4389-94. PubMed ID: 12677000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic factors MeCP2 and HDAC6 control α-tubulin acetylation in cardiac fibroblast proliferation and fibrosis.
    Tao H; Yang JJ; Shi KH; Li J
    Inflamm Res; 2016 May; 65(5):415-26. PubMed ID: 26975406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation.
    Wang Z; Leng Y; Wang J; Liao HM; Bergman J; Leeds P; Kozikowski A; Chuang DM
    Sci Rep; 2016 Jan; 6():19626. PubMed ID: 26790818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
    Zhang L; Liu C; Wu J; Tao JJ; Sui XL; Yao ZG; Xu YF; Huang L; Zhu H; Sheng SL; Qin C
    J Alzheimers Dis; 2014; 41(4):1193-1205. PubMed ID: 24844691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
    Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
    Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HDAC6 is a microtubule-associated deacetylase.
    Hubbert C; Guardiola A; Shao R; Kawaguchi Y; Ito A; Nixon A; Yoshida M; Wang XF; Yao TP
    Nature; 2002 May; 417(6887):455-8. PubMed ID: 12024216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of transcription factor XBP1s in the resistance of HDAC6 inhibitor Tubastatin A to superoxidation via acetylation-mediated proteasomal degradation.
    Zhang Y; Liu CM; Cao XC; Zang Y; Zhou YB; Li J
    Biochem Biophys Res Commun; 2014 Jul; 450(1):433-9. PubMed ID: 24909686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation.
    Matsuyama A; Shimazu T; Sumida Y; Saito A; Yoshimatsu Y; Seigneurin-Berny D; Osada H; Komatsu Y; Nishino N; Khochbin S; Horinouchi S; Yoshida M
    EMBO J; 2002 Dec; 21(24):6820-31. PubMed ID: 12486003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HDAC6 controls the kinetics of platelet activation.
    Sadoul K; Wang J; Diagouraga B; Vitte AL; Buchou T; Rossini T; Polack B; Xi X; Matthias P; Khochbin S
    Blood; 2012 Nov; 120(20):4215-8. PubMed ID: 22955928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant GlyRS-HDAC6 interaction linked to axonal transport deficits in Charcot-Marie-Tooth neuropathy.
    Mo Z; Zhao X; Liu H; Hu Q; Chen XQ; Pham J; Wei N; Liu Z; Zhou J; Burgess RW; Pfaff SL; Caskey CT; Wu C; Bai G; Yang XL
    Nat Commun; 2018 Mar; 9(1):1007. PubMed ID: 29520015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modification of cardiac disease by transgenically altered histone deacetylase 6.
    Sanbe A; Inomata Y; Matsushita N; Sawa Y; Hino C; Yamazaki H; Takanohashi K; Takahashi N; Higashio R; Tsumura H; Aoyagi T; Hirose M
    Biochem Biophys Res Commun; 2022 Nov; 631():48-54. PubMed ID: 36166953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.